(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/056449 A1

(51) International Patent Classification:
A61P 7/00 (2006.01) *C07D 417/14* (2006.01)
C07D 417/04 (2006.01) *A61K 31/427* (2006.01)

(21) International Application Number:
PCT/US2021/050216

(22) International Filing Date:
14 September 2021 (14.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/077,973 14 September 2020 (14.09.2020) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **DESAI, Kunal**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **FANG, Zhong**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **GUERTIN, Kevin**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **HONG, Vu**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **JIANG, John Ziqi**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **LIM, Sungtaek**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **LIU, Jinyu**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **MUNSON, Mark**; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/056449 A1

(54) Title: COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE

(57) Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.